Because only 4 blood samples from MS patients were currently applied to determine TCR diversities of CD8 + T cells in our studies, which might bring inadequate evidence thus impedes us to match the clonal expansion in peripheral with CD8 + T cell accumulation at lesion site during progression of MS. This evidence concerns the gene CD8A and myeloid sarcoma.